BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Doomed SpaceX Starlink satellite photographed from orbit- EU delegation urges China to tighten export controls
- ISS astronaut evacuation shouldn't interfere with upcoming Artemis 2 moon mission, NASA chief says
- I’m a dad to an autistic child. Here’s how you can make the holidays easier for all of us.
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- How Skoda Lost Its Biggest Market In Just Seven Years
- 'Something Very Bad Is Going to Happen' is the Duffer Brothers' first project since 'Stranger Things.' It's also 'wildly insane.'
- Hanwha Ocean secures orders worth $866m for five vessels
